Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR Trial

Summary

Phase 2 POLAR trial evaluating maintenance pembrolizumab + olaparib in biomarker-stratified metastatic PC. In cohort A (BRCA1/2, PALB2; n=33): median PFS 8.3 months, median OS 28 months, 3-year OS rate 44%. ctDNA response and enrichment of frameshift indel neoantigens were associated with durable clinical benefit.